SCHEMBL31160912

SCHEMBL31160912

CNC(=O)Cn1c(=O)[nH]c2ccc(C(=O)c3c(-c4ccccc4)c(OC)c4ccccn34)cc2c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ MAPK8 P45983 2/20 0.39
▸ MAPT P10636 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ELANE P08246 1/20 0.38
▸ GRIN1 Q05586 3/20 0.37
▸ GRIN2B Q13224 3/20 0.37
▸ KDM4E B2RXH2 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ GAA P10253 2/20 0.36
▸ MDM2 Q00987 1/20 0.36
▸ RXFP1 Q9HBX9 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ GLA P06280 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ S1PR2 O95136 1/20 0.36
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321669 0.92 HDAC1 (0.40) HDAC1HDAC6MAPK8MAPTMEN1
SCHEMBL31160996 0.89 HDAC1 (0.38) HDAC1HDAC6MAPK8MAPTMEN1
SCHEMBL31161028 0.87 TSPO (0.39) HDAC1HDAC6MAPK8MAPTMEN1
SCHEMBL14916426 0.82 MAPT (0.39) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL31161039 0.79 SMN1; SMN2 (0.36) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL14917190 0.77 NPC1 (0.40) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL15017204 0.75 KDM4E (0.39) MAPTKMT2AKDM4EALDH1A1GAA
SCHEMBL15067287 0.75 MAPT (0.35) MAPK8MAPTMEN1KMT2AKDM4E
SCHEMBL321863 0.74 CA12 (0.41) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL14916577 0.74 BRD4 (0.40) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
EP-4688756-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206345-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 HDAC1 1680/4885HDAC6 1296/4885MAPK8 1878/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 HDAC1 932/4885HDAC6 1073/4885MAPK8 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback